Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed)
ID: 351037Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351037

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-030.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed)" aimed at addressing the critical issue of adolescent illicit fentanyl use and overdose patterns among youth aged 12-18. This initiative encourages exploratory and developmental research to identify effective overdose prevention strategies and substance use disorder treatment methods, particularly focusing on high-risk adolescents and the alarming trends in overdose deaths, which saw a 94% increase from 2019 to 2020. The NIH anticipates committing approximately $1,000,000 to support 1-2 awards, with individual budgets capped at $275,000 over a two-year period. Applications are due by March 13, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-030-Full-Announcement.html
    RFA-DA-25-030.html
    The Department of Health and Human Services, through the National Institutes of Health, announces the Adolescent Overdose Prevention and SUD Treatment Initiative (R21), aimed at exploring and developing research that addresses adolescent illicit fentanyl use and overdose patterns. With a focus on at-risk adolescents aged 12-18, the initiative targets understanding the prevalence and underlying causes of overdose, especially related to fentanyl. It encourages innovative studies utilizing existing data or new methods to identify prevention and treatment engagement strategies. The funding opportunity anticipates committing approximately $1,000,000 to support 1-2 awards, with a budget capped at $275,000 over two years. Applications are encouraged from a diverse range of institutions, including higher education and nonprofit organizations, with specific eligibility guidelines outlined. The research efforts are vital due to alarming trends, highlighting a 94% increase in overdose deaths among adolescents from 2019 to 2020. The initiative is designed to ensure early intervention for overdose prevention and effective substance use treatment, with applications due by March 14, 2024. This funding initiative underscores the federal government's commitment to addressing public health challenges related to adolescent substance use and overdose crises.
    Similar Opportunities
    Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity for the development of medications aimed at preventing and treating substance use disorders (SUDs) and overdose. This initiative is structured into two phases: the UG3 phase focuses on achieving specific milestones within a two-year period, while the UH3 phase extends support for an additional three years for projects that successfully meet the UG3 milestones. Given the urgent need for effective treatments in light of rising overdose deaths, particularly from synthetic opioids and stimulants, this funding opportunity emphasizes innovative research methodologies and the effective application of existing medications. Interested applicants can seek funding of up to $3 million annually for a maximum of five years, with applications due by August 11, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-329.html.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data," aimed at supporting innovative analyses of existing datasets related to substance use behaviors, including alcohol, tobacco, and illicit drugs, and their connections to health outcomes such as HIV. This grant, classified as an R21 Clinical Trial Not Allowed, encourages applicants to utilize existing social science, behavioral, administrative, and neuroimaging data to enhance understanding of drug use behaviors, their consequences, and effective prevention and treatment strategies. A total of $2 million is available for projects over a two-year period, with individual application budgets capped at $275,000. Interested applicants must submit their proposals electronically through Grants.gov by December 3, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.
    Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials," aimed at encouraging pilot research to develop and test interventions that prevent or delay substance use. The initiative focuses on the creation and pilot testing of new or adapted strategies to curb substance misuse, particularly among underserved populations, while also addressing related negative outcomes such as impaired driving and transmission of infectious diseases. Eligible applicants include a wide range of institutions, such as academic, nonprofit, and government organizations, with funding available up to $450,000 over three years. Interested parties should note that applications are due starting January 16, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a grant opportunity titled the HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23), aimed at supporting early career researchers and clinicians in the field of addiction. Applicants are required to have clinical training and must propose an independent clinical trial that aligns with the HHS Overdose Prevention Strategy, focusing on areas such as opioid misuse prevention, treatment, harm reduction, and recovery support services. This initiative is crucial for addressing the ongoing substance use crisis by fostering a new generation of implementation researchers who can effectively translate research into clinical practice. Interested applicants can find more information and apply by November 12, 2025, with funding support of up to $100,000 per year for salary and additional research costs. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the opportunity's webpage at http://grants.nih.gov/grants/guide/pa-files/PAS-22-207.html.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01), aimed at supporting early career researchers in developing expertise in implementation science related to substance use treatment and prevention. Applicants are required to conduct an independent clinical trial that applies implementation science to one of the four priority domains of the HHS Overdose Prevention Strategy, which includes prevention, treatment, harm reduction, and recovery support services. This initiative is crucial in addressing the ongoing overdose crisis by promoting the integration of evidence-based practices into routine care, fostering a diverse research community, and ensuring equitable access to effective treatment resources. The funding amount is approximately $1.1 million for FY2023, with awards anticipated for 3-5 years of research, and applications are due by November 12, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.